Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

ooking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with Omeros' unproven preclinical and clinical development activities, regulatory oversight, commercialization of its products, intellectual property claims and the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.OMEROS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share and per share data)Three Months EndedNine Months EndedSeptember 30,September 30,2013201220132012(unaudited)(unaudited)Revenue

$
96

$
,417

$
,431

$
4,439Operating expenses:Research and development

9,420

7,764

26,111

22,568Selling, general and administrative

4,210

2,736

11,934

7,270Litigation settlement

-

3,953

-

3,953Total operating expenses

13,630

14,453

38,045

33,791Loss from operations

(13,434)

(13,036)

(36,614)

(29,352)Investment income

2

14

10

32Interest expense

(592)

(413)

(1,768)

(1,360)Other income, (expense) net

154

159

421

(30)Net loss

$
(13,870)


SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 2014 The Asian arthroscopic devices report ... analysis and forecast of revenue. The arthroscopic devices market ... by 2018, at a CAGR of 6.5% from 2013 ... Asian arthroscopic devices market, to get an idea of ... of the segmentation of arthroscopic devices market in the ...
(Date:10/18/2014)... October 18, 2014 The Asia-Pacific Liquid ... segments the concerned market in Asia-Pacific with analysis and ... million in 2013, and is expected to reach $380.0 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. This also provides ...
(Date:10/18/2014)... October 18, 2014 The Biomass ... in the five years to 2014. The industry's expansion ... energy tax credits that encouraged the use of biomass ... portfolio standards (RPSs), which require local utilities to generate ... total energy portfolio. Increased campaigning for green technology also ...
(Date:10/18/2014)... The report " Cloud Analytics Market ... Speech; Machine; Video; Predictive Analytics: Global Advancements, Delivery ... Analysis (2013 - 2018) ", defines and segments ... segments with an in-depth analysis and forecasting of ... driving this market, various restraints, and opportunities impacting ...
Breaking Biology Technology:The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 2Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5
... it doesn,t just go to his or her head: It ... biomolecules that may serve as a permanent record of each ... Act grant from the National Institute of Drug Abuse (NIDA) ... physicist John Wikswo will attempt to determine whether an individual,s ...
... - Oncothyreon Inc. (NASDAQ: ONTY ) today reported financial ... 2009 and provided a product pipeline update. Management will hold ... PT (see below for details). , Oncothyreon reported a loss ... September 30, 2009, compared with a loss from operations of ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: ... and advances a diverse portfolio of promising cancer-related products ... financial results for the first quarter of fiscal 2010, ... quarter, we continued to advance our lead drug nimotuzumab, ...
Cached Biology Technology:Interdisciplinary research team developing novel drug detection technology 2Interdisciplinary research team developing novel drug detection technology 3Interdisciplinary research team developing novel drug detection technology 4Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 2Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 3Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 4Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 5Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 6Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 7Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 2YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 3YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 4YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 5YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 6YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 7YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 9YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 10YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 11YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 12
(Date:10/14/2014)... 14, 2014 – High doses of fish oil supplements, rich ... common type of irregular heartbeat in which the heart can ... of the AFFORD trial led by the Montreal Heart Institute ... of Cardiology on October 7th. , For the trial, ... were randomly assigned to 4 grams of fish oil a ...
(Date:10/14/2014)... international team of researchers, led by the Chinese Academy ... Nature Genetics a brief genomic history of ... the tomato plant. , The C.M. Rick Tomato Genetics ... in this study by providing seed of both cultivated ... which builds on the first tomato genome sequence completed ...
(Date:10/14/2014)... 2014 – Researchers from Stanford University School of Medicine ... by cells and the activation of muscle stem cells. ... generate energy during times of nutrient deprivation. The scientists ... this protective mechanism is operational it also seems to ... reveals that when stem cells emerge from a quiescent ...
Breaking Biology News(10 mins):Autophagy helps fast track stem cell activation 2
... MD (July 27, 2010) -- Fluids experts writing in ... published by the American Institute of Physics, are projecting ... probe the properties of turbulence near walls. High-Reynolds-number flows ... aeronautics, naval applications, energy conversion processes, manufacturing, mixing and ...
... be difficult for scientists to see the deforestation for the ... of the Brown-MBL Graduate Program in Biological and Environmental Sciences ... and her colleagues, who take a big-picture approach to greenhouse ... Proceedings of the National Academy of Sciences , the team ...
... release is available in Spanish . ... for deciphering the genetics of a native prairie grass being ... genetic map of switchgrass, published by Christian Tobias, a molecular ... Calif., and his colleagues, is expected to speed up the ...
Cached Biology News:A future with or without trees 2A new tool for improving switchgrass 2
A collection of 42 spots with normal tissues from different organs of C57 mice, rat and human....
... The V-106 voice-coil scanning and positioning ... small samples have to be positioned ... high resolution. It provides superior responsiveness ... drives. The mechanics (X or XY ...
Improves spot morphology and DNA binding to the slide resulting in increased hybridization signal. ID Clarifier: Optimized spotting solution for use with SigmaScreen APS Coated Slides for Microarrays...
... General description: Humidity wells in the base ... chamber humidity and probe hydration around the ... eliminates the risk of waterbath contamination. This ... temperature waterbaths or hybridisation ovens. Linkage: This ...
Biology Products: